MCQ: Recent FDA approvals-3 (April 2019)

 20%

Question 1 of 5

1. Which of the following has been approved for the treatment of newly-diagnosed acute myeloid leukemia in adults 75 years of age or older in 2018?

A.
B.
C.
D.

Question 1 of 5

Question 2 of 5

2. Which of the following is recombinant modified factor Xa protein that has been developed as a universal antidote to reverse anticoagulant effects of direct or indirect factor Xa inhibitors and approved in May 2018 ?

A.
B.
C.
D.

Question 2 of 5

Question 3 of 5

3. Which of the following drug has been recently approved (December 21, 2018) for adult patients with paroxysmal nocturnal hemoglobinuria (PNH)?

A.
B.
C.
D.

Question 3 of 5

Question 4 of 5

4. Which of the following has been recently approved for the treatment of acquired thrombotic thrombocytopenic purpura in February 2019 ?

A.
B.
C.
D.

Question 4 of 5

Question 5 of 5

5. Hematological indication for Keytruda (pembrolizumab) as of now (April 2019) is in ?

A.
B.
C.
D.

Question 5 of 5


 

One thought on “MCQ: Recent FDA approvals-3 (April 2019)”

Leave a Reply